Targeted mutational landscape of the molecular study cohort. The Oncoprint shows recurrently mutated genes as rows and the 157 patients of the molecular study cohort as columns by randomization status. The color coding delineates the type of nonsynonymous alteration detected by targeted next-generation sequencing of 51 genes. The top annotation indicates FLIPI, m7-FLIPI, and POD24-PI risk groups. For BCL2 (bottom annotation), all variants including silent and noncoding variants were reported as hypermutations. The number of cases with respective gene mutations and corresponding mutation frequencies by cohort are visualized on the right side of the Oncoprints.